Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Vitamin B3, also known as niacin, plays a vital role in maintaining a healthy liver. It helps the liver process fats efficiently, reduces inflammation, and supports detoxification. This essential ...

New research highlights Vitamin B3, specifically nicotinamide, as a potential chemopreventive agent against skin cancer. Studies indicate that daily supplementation can reduce skin cancer risk by up ...

A major shift is unfolding in the field of skin cancer prevention, ignited by new research showing that an everyday vitamin supplement may prevent many cases of the world’s most frequently diagnosed ...

A common vitamin could help prevent the development of skin cancer, new research suggests. The study, published in JAMA Dermatology, found a decreased risk of three types of skin cancer associated ...

A form of B3 called nicotinamide cut the risk of developing repeat skin cancers by as much as 54 percent, according to new research. A large new study found that nicotinamide, a form of vitamin B3, ...

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after reporting positive results in a phase 3 trial. Full data from the ...

A common, over-the-counter form of vitamin B3 has emerged as an inexpensive ally in protecting us from skin cancer, lowering the risk by an average of 14% and increasing to a massive 54% for anyone ...

Researchers at the University of California, Irvine have identified a promising nonpharmaceutical treatment that rejuvenates aging brain cells and clears away the buildup of harmful proteins ...

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...